1 / 20

Iatrogenic Heart Disease aegrescit medendo the remedy is worse than the disease

I. Iatrogenic

harmon
Télécharger la présentation

Iatrogenic Heart Disease aegrescit medendo the remedy is worse than the disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Iatrogenic Heart Disease aegrescit medendo (the remedy is worse than the disease) Gregory L. Sheehy, M.D. Primary Care Conference May 10, 2006

    2. I. Iatrogenica definition Induced in a patient by a physicians words or actions The American Heritage Dictionary, 2nd Ed.

    3. OR An iatrogenic disorder occurs when the deleterious effects of a therapeutic or diagnostic regimen cause pathology However, the harm that a physician can do is not limited to the imprudent use of medications or procedures. Equally important are ill-considered or unjustified remarks. Harrisons Principles of Internal Medicine, 14th ed., p. 4

    4. II. Case Report First visit 01/02/1998 (transferring from another clinic) 63 year old woman who feels well but is recovering from a recent traumatic L1 compression fracture Other problems: Hypertension-145/75-Atenolol 50mg/Amlodipine 5mg Hypertriglyceridemia-Gemfibrozil 300 mg bid Asymptomatic diverticulosis Asymptomatic mitral valve prolapse-no murmur noted-? Click Vaginal hysterectomy and cholecystectomy, remote Treatment plan: Medications renewed Scheduled for complete exam in April of 1998 Patient leaving for Arizona for the remainder of the winter

    5. Case Report, cont. Flash forward to CPE 11/11/05, patient now 71 years Problem list Hypertension-110/70-Atenolol 50 mg/Amlodipine 5mg Occasional mild exertional chest pain Cold/numb feet-improved with brief trial off atenolol Hypertriglyceridemia-Gemfibrozil 600 mg bid Recurrent UTIs with significant episode of pyelonephritis in July 2004 Recurrent episodes of diverticulitis (3 in all) with colonoscopy in 2003, unremarkable except for tics S/p acute appendicitis with perforation/peritonitis in June 2002 H/o mitral valve prolapse with echocardiogram in May, 1999, showing no MVP/regurgitation S/p vaginal hyst and cholecystectomy, remote At this visit, her most significant complaint is that the cold feet and somewhat numb sensation in her feet is something that she is finding pretty intolerable The incidence of cold extremities during atenolol treatment was 58% in one study, Feleke et al, 1983, Micromedex

    6. Case Report, cont. Treatment plan Taper off Atenolol Discontinue Amlodipine Gradual start of Lisinopril 20mg/HCTZ 12.5 mg Recheck in 2 weeks

    7. Case Report, cont. Return visit approximately 10 days later, 11/22/05, on Lisinopril and HCTZ Problem list Hypertension-100/60 in both arms Chest pain, not severe, but clearly worse Faster HR/palpitations/DOE-no PND New cardiac murmur-quite loud-IV/VI pansystolic murmur with thrill all over precordium and around to her back and very active precordium Studies EKG: LVH with poor R wave progression, no acute ischemic changes Chest xray: normal Enzymes/lytes: normal except for creatinine of 1.5, a rise Plan Patient did not look acutely ill but was obviously uncomfortable Admit for evaluation and treatment Metoprolol 50 mg given immediatelywithin one hour, she started to feel better Endocarditis/ruptured valve leaflet/aortic dissection under consideration

    8. III. Major Learning ObjectiveLook at all of the data!

    9. My bias failed me: You see only what you look for and recognize what you know

    10. Echocardiogram, 5/28/99 No significant valvular disease, specifically, there is no mitral valve prolapse or regurgitation. Asymmetric septal hypertrophy with no systolic anterior motion of the mitral valve. Left ventricular size is normal and systolic function is hyperdynamic with an estimated ejection fraction of 75%. There is evidence for delayed left ventricular relaxation.

    11. Echocardiogram, 11/23/05 Overall systolic function is hyperdynamic. Moderate systolic anterior motion of the mitral valve is noted. There is dynamic left ventricular outflow tract obstruction at rest, with a peak velocity of 3.5m/sec, and a peak gradient of 49 mmHg. Moderate valvular regurgitation of the mitral valve.

    12. What happened?...I had unmasked Hypertrophic Cardiomyopathy

    13. Why? Stopped beta blocker- increased heart rate Started ACE inhibitor with a diuretic- decreased preload and afterload

    14. Follow up Patient now on Verapamil 240 mg SR twice daily and feels well

    15. IV. Hypertrophic Cardiomyopathy (HCM) It is an autosomal dominant genetic disease All first degree relatives should get tested yearly ages 12 to 18 and every 5 years from age 18 to ? (delayed onset of hypertrophy is an issue) Echocardiogram is the screening test of choice Most electrocardiograms are abnormal with LVH and often ST-T wave changes A normal ECG in HCM is unusual

    16. HCM, cont. Prevalence of HCM is somewhere between 1:350 to 1:650 individuals Many patients with HCM have no symptoms and therefore many cases are found by screening. The issue is that a significant portion (25-40%) will eventually develop symptoms Most common symptom is dyspnea with exertion (DOE) Other symptoms include chest pain, presyncope/syncope, and palpitations Women tend to have more symptoms with advancing age This is possibly due to smaller LV cavity size

    17. HCM, cont. Worse prognosis Early age at onset (i.e. < 20 years of age) Severity of symptoms at time of diagnosis Variable other clinical markers Outflow gradient > 30 mmHg LV wall thickness >25 mm Atrial fibrillation Mortality rates of men=women The usual stated annual mortality rate of 3-5% is too highprobably closer to 1%

    18. Key Exam Findings A murmur that increases from a change from sitting or squatting to the upright position A murmur that decreases going from a standing to sitting, squatting, or lying position

    19. Treatment Medications Beta blockers Verapamil Disopyramide Other Surgical resection Chemical ablation Defibrillator Heart transplant

    20. References Up to Date 2006, Hypertrophic Cardiomyopathy Maron BJ, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-655. Olivetto I, Maron MS, Adabog AS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46: 480-7.

More Related